Why the Volpara Health Technologies Ltd share price is up 4% today

The share price of digital health company Volpara Health Technologies Ltd (ASX: VHT) has risen 4.86% to 75.5 cents in Tuesday’s trading session following this morning’s announcement that it has exceeded its commercial target of 200% growth in Annual Recurring Revenue (ARR) for the 2018 financial year.

ARR exceeds guidance

The company’s ARR now stands at NZ$3.6 million, which is a 223% increase on the NZ$1.1 million in ARR it posted in the 2017 financial year. Furthermore, Total Contract Value (TCV) has now exceeded NZ$11.2 million, an impressive gain of 173% on the prior financial year’s total of NZ$4.1 million. Volpara also announced that the amount of VolparaEnterprise customers has risen from 14 to 57 over the last 12 months.

Volpara has also exceeded its 3.0% target for the amount of women to be screened in the United States using its software. Approximately 3.2% of all women screened in the United States are now contracted to Volpara’s software.

Foolish takeaway 

Volpara remains one of the most intriguing small cap stocks on the Australian stock market. It provides a unique alternative to other small cap healthcare stocks such as Paragon Care Ltd (ASX: PGC) and Zenitas Healthcare Limited (ASX: ZNT). Volpara is focused on the early detection of breast cancer by enhancing the quality of screening through the use of artificial intelligence. The company’s clinical support software provides feedback in real-time whilst its enterprise wide software, VolparaEnterprise, helps breast clinics manage their businesses by offering a centralized overview and a wide range of benchmarking measures.

The company is expanding geographically after it was selected for a further 2 year trial by the United Kingdom’s National Health Service (NHS) to implement VolparaDensity software across a number of locations as part of its Breast Screening Programme.  Regulatory clearances to operate in Taiwan and Japan have also been obtained. Investors can now look forward to the company’s results for the financial year ended 31 March 2018, which are expected to be released towards the end of April.

The Disruptors: 3 Revolutionary Aussie Companies to Back for 2018

We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.

That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Cochlear or REA Group.

We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!

Motley Fool Contributor Tim Katavic has no financial interest in any company mentioned. The Motley Fool Australia owns shares of VOLPARA FPO NZ. The Motley Fool Australia has recommended Paragon Care Limited and Zenitas Healthcare Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.